 | • レポートコード：MRC2-11QY12250 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はヒト免疫不全ウイルス（HIV）-1治療薬のグローバル市場について調査・分析したレポートです。種類別（ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI）、侵入・融合阻害剤、プロテアーゼ阻害剤（PI）、インテグラーゼ阻害剤、共受容体拮抗薬）市場規模、用途別（病院、クリニック、ラボ）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ヒト免疫不全ウイルス（HIV）-1治療薬の競争状況、市場シェア ・世界のヒト免疫不全ウイルス（HIV）-1治療薬市場：種類別市場規模 2015年-2020年（ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI）、侵入・融合阻害剤、プロテアーゼ阻害剤（PI）、インテグラーゼ阻害剤、共受容体拮抗薬） ・世界のヒト免疫不全ウイルス（HIV）-1治療薬市場：種類別市場規模予測 2021年-2026年（ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI）、侵入・融合阻害剤、プロテアーゼ阻害剤（PI）、インテグラーゼ阻害剤、共受容体拮抗薬） ・世界のヒト免疫不全ウイルス（HIV）-1治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、ラボ） ・世界のヒト免疫不全ウイルス（HIV）-1治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、ラボ） ・北米のヒト免疫不全ウイルス（HIV）-1治療薬市場分析：米国、カナダ ・ヨーロッパのヒト免疫不全ウイルス（HIV）-1治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのヒト免疫不全ウイルス（HIV）-1治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のヒト免疫不全ウイルス（HIV）-1治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのヒト免疫不全ウイルス（HIV）-1治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AbbVie, Inc.(U.S.)、Merck & Co., Inc. (U.S.)、Bristol-Myers Squibb Company (U.S.)、Boehringer Ingelheim GmbH (Germany)、Genentech, Inc. (U.S.)、Cipla, Inc. (India) ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.
Market Analysis and Insights: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market size is projected to reach US$ 11980 million by 2026, from US$ 11880 million in 2020, at a CAGR of 0.8%% during 2021-2026.
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Scope and Market Size
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)
…
Market segment by Type, the product can be split into
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Market segment by Application, split into
Hospitals
Clinics
Labs
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
1.4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.4.4 Entry and Fusion Inhibitors
1.4.5 Protease Inhibitors (PIs)
1.4.6 Integrase Inhibitors
1.4.7 Coreceptor Antagonists
1.5 Market by Application
1.5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Labs
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Perspective (2015-2026)
2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Growth Trends by Regions
2.2.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Human Immunodeficiency Virus (HIV)-1 Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Market Size
3.1.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio
3.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2019
3.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players Head office and Area Served
3.4 Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Solution and Service
3.5 Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2020)
6.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in North America (2019-2020)
6.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
6.4 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2020)
7.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
7.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2020)
8.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in China (2019-2020)
8.3 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
8.4 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2020)
9.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
9.4 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2020)
10.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2020)
11.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in India (2019-2020)
11.3 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
11.4 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2020)
12.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AbbVie, Inc.(U.S.)
13.1.1 AbbVie, Inc.(U.S.) Company Details
13.1.2 AbbVie, Inc.(U.S.) Business Overview
13.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
13.1.4 AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020))
13.1.5 AbbVie, Inc.(U.S.) Recent Development
13.2 Merck & Co., Inc. (U.S.)
13.2.1 Merck & Co., Inc. (U.S.) Company Details
13.2.2 Merck & Co., Inc. (U.S.) Business Overview
13.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
13.2.4 Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
13.2.5 Merck & Co., Inc. (U.S.) Recent Development
13.3 Bristol-Myers Squibb Company (U.S.)
13.3.1 Bristol-Myers Squibb Company (U.S.) Company Details
13.3.2 Bristol-Myers Squibb Company (U.S.) Business Overview
13.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
13.3.4 Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
13.3.5 Bristol-Myers Squibb Company (U.S.) Recent Development
13.4 Boehringer Ingelheim GmbH (Germany)
13.4.1 Boehringer Ingelheim GmbH (Germany) Company Details
13.4.2 Boehringer Ingelheim GmbH (Germany) Business Overview
13.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
13.4.4 Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
13.4.5 Boehringer Ingelheim GmbH (Germany) Recent Development
13.5 Genentech, Inc. (U.S.)
13.5.1 Genentech, Inc. (U.S.) Company Details
13.5.2 Genentech, Inc. (U.S.) Business Overview
13.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
13.5.4 Genentech, Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
13.5.5 Genentech, Inc. (U.S.) Recent Development
13.6 Cipla, Inc. (India)
13.6.1 Cipla, Inc. (India) Company Details
13.6.2 Cipla, Inc. (India) Business Overview
13.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
13.6.4 Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
13.6.5 Cipla, Inc. (India) Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue
Table 3. Ranking of Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Table 6. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 7. Key Players of Entry and Fusion Inhibitors
Table 8. Key Players of Protease Inhibitors (PIs)
Table 9. Key Players of Integrase Inhibitors
Table 10. Key Players of Coreceptor Antagonists
Table 11. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions (2015-2020)
Table 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Growth Strategy
Table 21. Main Points Interviewed from Key Human Immunodeficiency Virus (HIV)-1 Therapeutics Players
Table 22. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 23. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Players (2015-2020)
Table 24. Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics as of 2019)
Table 25. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Solution and Service
Table 28. Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 31. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Share by Type (2015-2020)
Table 32. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Type (2021-2026)
Table 33. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Share by Application (2015-2020)
Table 34. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 35. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Share by Application (2021-2026)
Table 36. North America Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share (2019-2020)
Table 38. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 39. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2015-2020)
Table 40. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 41. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2015-2020)
Table 42. Europe Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share (2019-2020)
Table 44. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2015-2020)
Table 46. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2015-2020)
Table 48. China Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (2019-2020) (Million US$)
Table 49. China Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share (2019-2020)
Table 50. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 51. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2015-2020)
Table 52. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 53. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2015-2020)
Table 54. Japan Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share (2019-2020)
Table 56. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2015-2020)
Table 58. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share (2019-2020)
Table 62. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2015-2020)
Table 64. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2015-2020)
Table 66. India Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (2019-2020) (Million US$)
Table 67. India Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share (2019-2020)
Table 68. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 69. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2015-2020)
Table 70. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 71. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share (2019-2020)
Table 74. Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type (2015-2020)
Table 76. Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application (2015-2020)
Table 78. AbbVie, Inc.(U.S.) Company Details
Table 79. AbbVie, Inc.(U.S.) Business Overview
Table 80. AbbVie, Inc.(U.S.) Product
Table 81. AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020) (Million US$)
Table 82. AbbVie, Inc.(U.S.) Recent Development
Table 83. Merck & Co., Inc. (U.S.) Company Details
Table 84. Merck & Co., Inc. (U.S.) Business Overview
Table 85. Merck & Co., Inc. (U.S.) Product
Table 86. Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020) (Million US$)
Table 87. Merck & Co., Inc. (U.S.) Recent Development
Table 88. Bristol-Myers Squibb Company (U.S.) Company Details
Table 89. Bristol-Myers Squibb Company (U.S.) Business Overview
Table 90. Bristol-Myers Squibb Company (U.S.) Product
Table 91. Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020) (Million US$)
Table 92. Bristol-Myers Squibb Company (U.S.) Recent Development
Table 93. Boehringer Ingelheim GmbH (Germany) Company Details
Table 94. Boehringer Ingelheim GmbH (Germany) Business Overview
Table 95. Boehringer Ingelheim GmbH (Germany) Product
Table 96. Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020) (Million US$)
Table 97. Boehringer Ingelheim GmbH (Germany) Recent Development
Table 98. Genentech, Inc. (U.S.) Company Details
Table 99. Genentech, Inc. (U.S.) Business Overview
Table 100. Genentech, Inc. (U.S.) Product
Table 101. Genentech, Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020) (Million US$)
Table 102. Genentech, Inc. (U.S.) Recent Development
Table 103. Cipla, Inc. (India) Company Details
Table 104. Cipla, Inc. (India) Business Overview
Table 105. Cipla, Inc. (India) Product
Table 106. Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020) (Million US$)
Table 107. Cipla, Inc. (India) Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Features
Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Features
Figure 4. Entry and Fusion Inhibitors Features
Figure 5. Protease Inhibitors (PIs) Features
Figure 6. Integrase Inhibitors Features
Figure 7. Coreceptor Antagonists Features
Figure 8. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Labs Case Studies
Figure 12. Human Immunodeficiency Virus (HIV)-1 Therapeutics Report Years Considered
Figure 13. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions: 2020 VS 2026
Figure 15. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Players in 2019
Figure 18. Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2019
Figure 20. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
HIV治療薬の世界市場（～2026年） The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease. HIV spreads through fluidic …- ヒト免疫不全ウイルス（HIV）の世界市場（～2026年） HIV (Human immunodeficiency virus) is a retrovirus which causes HIV infection and attacks the CD-4 cells (T-cells) in the immune system of human body. HIV reduces the number of T-cells in the body and makes the immune system vulnerable to life-threatening infections and cancers. An infected person c…
- テロメラーゼ逆転写酵素の世界市場（～2026年） Market Analysis and Insights: Global Telomerase Reverse Transcriptase Market The global Telomerase Reverse Transcriptase market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Telomerase Reverse Transcriptase Scope and Market…
- HIV薬の世界市場（～2026年） HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. The global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population. One…
- TNF阻害剤の世界市場（～2026年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…